The Effect of Topical Bevacizumab on Corneal Neovascularization

Sang Woo Kim, Byung Jin Ha, Eungkweon Kim, Hungwon Tchah, Tae-im Kim

Research output: Contribution to journalArticle

152 Citations (Scopus)

Abstract

Purpose: To examine the effect of topical bevacizumab on corneal neovascularization (NV) over a period of 3 months. Design: Prospective, nonrandomized, masked observational case series. Participants: Ten eyes of 7 patients with corneal NV. Methods: Patients received topical bevacizumab (1.25%) twice daily. Ophthalmic evaluations included visual acuity, slit-lamp examination, and tonometry. Main Outcome Measures: Corneal NV and changes in ophthalmic evaluations. Results: Decreased corneal NV was noted in 7 of 10 eyes, usually within 1 month of treatment. Epitheliopathy (epithelial defect, epithelial erosion) was observed in 6 of 10 eyes, 1 resulting in corneal thinning. Adverse effects generally appeared during the second month of treatment. Conclusions: Topical application of bevacizumab was effective in reducing corneal NV within the first month. However, by the second month there was an increased risk of adverse effects.

Original languageEnglish
JournalOphthalmology
Volume115
Issue number6
DOIs
Publication statusPublished - 2008 Jun 1

Fingerprint

Corneal Neovascularization
Manometry
Visual Acuity
Outcome Assessment (Health Care)
Bevacizumab
Therapeutics

All Science Journal Classification (ASJC) codes

  • Ophthalmology

Cite this

Kim, Sang Woo ; Ha, Byung Jin ; Kim, Eungkweon ; Tchah, Hungwon ; Kim, Tae-im. / The Effect of Topical Bevacizumab on Corneal Neovascularization. In: Ophthalmology. 2008 ; Vol. 115, No. 6.
@article{c80dcf406baa459395435cdc2e9d7453,
title = "The Effect of Topical Bevacizumab on Corneal Neovascularization",
abstract = "Purpose: To examine the effect of topical bevacizumab on corneal neovascularization (NV) over a period of 3 months. Design: Prospective, nonrandomized, masked observational case series. Participants: Ten eyes of 7 patients with corneal NV. Methods: Patients received topical bevacizumab (1.25{\%}) twice daily. Ophthalmic evaluations included visual acuity, slit-lamp examination, and tonometry. Main Outcome Measures: Corneal NV and changes in ophthalmic evaluations. Results: Decreased corneal NV was noted in 7 of 10 eyes, usually within 1 month of treatment. Epitheliopathy (epithelial defect, epithelial erosion) was observed in 6 of 10 eyes, 1 resulting in corneal thinning. Adverse effects generally appeared during the second month of treatment. Conclusions: Topical application of bevacizumab was effective in reducing corneal NV within the first month. However, by the second month there was an increased risk of adverse effects.",
author = "Kim, {Sang Woo} and Ha, {Byung Jin} and Eungkweon Kim and Hungwon Tchah and Tae-im Kim",
year = "2008",
month = "6",
day = "1",
doi = "10.1016/j.ophtha.2008.02.013",
language = "English",
volume = "115",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "6",

}

The Effect of Topical Bevacizumab on Corneal Neovascularization. / Kim, Sang Woo; Ha, Byung Jin; Kim, Eungkweon; Tchah, Hungwon; Kim, Tae-im.

In: Ophthalmology, Vol. 115, No. 6, 01.06.2008.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The Effect of Topical Bevacizumab on Corneal Neovascularization

AU - Kim, Sang Woo

AU - Ha, Byung Jin

AU - Kim, Eungkweon

AU - Tchah, Hungwon

AU - Kim, Tae-im

PY - 2008/6/1

Y1 - 2008/6/1

N2 - Purpose: To examine the effect of topical bevacizumab on corneal neovascularization (NV) over a period of 3 months. Design: Prospective, nonrandomized, masked observational case series. Participants: Ten eyes of 7 patients with corneal NV. Methods: Patients received topical bevacizumab (1.25%) twice daily. Ophthalmic evaluations included visual acuity, slit-lamp examination, and tonometry. Main Outcome Measures: Corneal NV and changes in ophthalmic evaluations. Results: Decreased corneal NV was noted in 7 of 10 eyes, usually within 1 month of treatment. Epitheliopathy (epithelial defect, epithelial erosion) was observed in 6 of 10 eyes, 1 resulting in corneal thinning. Adverse effects generally appeared during the second month of treatment. Conclusions: Topical application of bevacizumab was effective in reducing corneal NV within the first month. However, by the second month there was an increased risk of adverse effects.

AB - Purpose: To examine the effect of topical bevacizumab on corneal neovascularization (NV) over a period of 3 months. Design: Prospective, nonrandomized, masked observational case series. Participants: Ten eyes of 7 patients with corneal NV. Methods: Patients received topical bevacizumab (1.25%) twice daily. Ophthalmic evaluations included visual acuity, slit-lamp examination, and tonometry. Main Outcome Measures: Corneal NV and changes in ophthalmic evaluations. Results: Decreased corneal NV was noted in 7 of 10 eyes, usually within 1 month of treatment. Epitheliopathy (epithelial defect, epithelial erosion) was observed in 6 of 10 eyes, 1 resulting in corneal thinning. Adverse effects generally appeared during the second month of treatment. Conclusions: Topical application of bevacizumab was effective in reducing corneal NV within the first month. However, by the second month there was an increased risk of adverse effects.

UR - http://www.scopus.com/inward/record.url?scp=44449119809&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44449119809&partnerID=8YFLogxK

U2 - 10.1016/j.ophtha.2008.02.013

DO - 10.1016/j.ophtha.2008.02.013

M3 - Article

VL - 115

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 6

ER -